查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046884

眼內壓高血壓治療市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年

Ocular Hypertension Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Route Of Administration, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球眼壓升高治療市場預計將從 2025 年的 37.8 億美元成長到 2031 年的 47.4 億美元，複合年成長率為 3.84%。

該市場涵蓋旨在控制眼內壓升高並預防青光眼性視神經病變的藥物和手術療法。推動該市場成長的關鍵因素包括全球人口加速老化以及糖尿病和高血壓等全身性疾病盛行率的上升，這些疾病被認為是眼部併發症的重要風險因素。這些人口結構和健康狀況的變化正在催生對高效眼內壓管理解決方案的持續需求，而這種需求在很大程度上獨立於暫時的技術進步。

市場概覽
預測期： 2027-2031
市場規模：2025年 37.8億美元
市場規模：2031年 47.4億美元
複合年成長率：2026-2031年 3.84%
成長最快的細分市場 網路藥房
最大的市場 北美洲

然而，阻礙市場快速擴張的一大障礙是患者普遍存在的用藥依從性問題。這種依從性問題通常是由於局部用藥沒有症狀或不適感所致。美國眼科學會 (AAO) 最新發布的流行病學數據顯示，2025 年美國約有 420 萬成年人患有青光眼，凸顯了早期持續控制眼壓升高對於預防不可逆視力喪失至關重要。

市場促進因素

市場成長的主要促進因素是全球眼壓升高和開放性青光眼盛行率的不斷上升，而這主要是由於人口老化導致視神經損傷風險增加所致。患者數量的增加使得人們對傳統眼藥水治療以外的先進眼壓管理技術產生了持續且迫切的需求。隨著這些疾病發病率的上升，醫療保健系統面臨越來越大的壓力，需要優先考慮早期療育以保護視力。 2024年11月發表在《全球健康雜誌》（Journal of Global Health）上的一項題為“全球青光眼發病率和危險因素”的研究估計，40至79歲人群中原發性開放性青光眼的全球發病率為每萬人年23.46例，這表明目標人口正在迅速擴大，直接推動了對青光眼治療方法和手術治療方法的需求。

同時，技術創新，特別是緩釋藥物輸送系統和微創青光眼手術（MIGS）領域的創新，正在有效解決眼藥水依從性這一長期難題，從而改變治療模式。隨著醫療專業人員積極採用可確保藥物持續釋放或促進房水排出的植入式裝置，這些創新正獲得顯著的市場滲透。 Glaukos公司於2025年2月發布的2024會計年度第四季及全年財報強調了這些新療法的強勁市場接受度，青光眼相關產品的淨銷售額創歷史新高，達到3.033億美元。整個產業的趨勢也支持這種向手術和器械治療的轉變。根據愛爾康公司2025年2月發布的報告，2024會計年度手術相關產品的淨銷售額達到55億美元，凸顯了先進眼科干預措施的巨額資金投入。

市場挑戰

患者對長期藥物治療的依從性低是全球眼壓升高治療市場成長的一大障礙。由於缺乏明顯症狀以及眼部刺激等副作用帶來的不適，患者往往不願意堅持治療，導致治療中斷和處方箋續開率低。直接後果是，製藥公司持續遭受收入損失，阻礙了市場充分發揮其經濟潛力。處方治療方案與患者實際用藥行為之間的差異導致疾病管理效率低下，並直接影響市場成長預期。

該疾病在全球範圍內的高發病率進一步凸顯了這項挑戰的嚴峻性。儘管如此高的發病率意味著龐大的潛在消費群體，但藥物依從性問題意味著相當一部分患者仍無法獲得治療。世界青光眼協會報告稱，到2025年，全球預計將有7,800萬人被診斷出患有青光眼。雖然這一數字代表著龐大的潛在市場，但低藥物依從率意味著相當一部分患者實際上並未接受治療或病情控制不佳。這種持續存在的藥物依從性差距阻礙了治療的廣泛應用，並削弱了全球治療市場的整體發展勢頭。

市場趨勢

隨著家用眼壓監測設備的普及，眼高壓的管理方式正在發生變革，因為這些設備能夠檢測到日間眼壓波動，而這些波動往往在零星的門診就診中被忽略。這些攜帶式技術使患者能夠在診室外持續測量眼壓，為臨床醫生提供大量數據，以便制定個人化的治療方案，並識別在正常診療時間之外發生的眼壓高峰。由於醫療機構致力於降低與不可控眼壓波動相關的風險，這種以患者為中心的遠端監測模式正吸引商業性的關注。根據Revenio集團於2025年2月發布的“2024年1月1日至12月31日財務業績報告”，全年淨銷售額達到1.035億歐元，年增7.2%。這主要得益於家用眼壓計解決方案的強勁銷售成長。

同時，人工智慧在疾病進展分析中的應用正在提高診斷準確性。目前，深度學習技術已被用於比傳統方法更早識別視神經的細微變化。這些自動化系統分析龐大的影像資料集，提供客觀的風險評估，從而最大限度地減少人工評估中固有的主觀差異。這項技術進步使得在不可逆的視力喪失發生之前進行快速干涉成為可能，滿足了繁忙的臨床環境中對可擴展且準確的篩檢工具的迫切需求。美國眼科學會 (AAO) 於 2025 年 10 月發布了一份題為“人工智慧驅動的青光眼篩檢取得令人矚目的成果”的新聞稿，其中報告的研究表明，一種新的機器學習演算法能夠以 88% 至 90% 的準確率識別青光眼患者，超過了訓練有素的人工評估人員 79% 至 81% 的準確率。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球眼壓升高治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（眼壓升高、青光眼）
    • 給藥途徑（口服、腸外、其他）
    • 分銷通路（零售藥局、網路藥局、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美高血壓治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲高血壓治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區高血壓治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東與非洲高眼壓治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美高血壓治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布

第13章 全球高血壓治療市場：SWOT分析

第14章：波特五力分析

  • 產業內部的競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Angelini Spa
  • Laboratorios Sophia
  • Neurim Pharmaceuticals Ltd
  • Nicox SA
  • Novartis AG.
  • Aerie Pharmaceuticals, Inc.
  • Abbvie, Inc
  • Angelini Pharma Spa
  • Chong Kun Dang pharmaceutical Corp
  • Lee Pharma Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18937

The global market for ocular hypertension treatments is projected to expand from USD 3.78 billion in 2025 to USD 4.74 billion by 2031, demonstrating a compound annual growth rate (CAGR) of 3.84%. This market encompasses both pharmaceutical and surgical strategies aimed at reducing elevated intraocular pressure and thereby preventing the progression to glaucomatous optic neuropathy. Key factors fueling this market growth include the accelerating aging of the global population and the rising incidence of systemic health conditions such as diabetes and hypertension, both recognized as significant risk factors for ocular complications. These inherent demographic and health transformations ensure a consistent demand for efficient intraocular pressure management solutions, largely independent of temporary technological shifts.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.78 Billion
Market Size 2031USD 4.74 Billion
CAGR 2026-20313.84%
Fastest Growing SegmentOnline Pharmacy
Largest MarketNorth America

Nevertheless, a notable obstacle hindering swift market expansion is the prevalent issue of patient non-adherence to sustained medication protocols. This non-compliance frequently arises from the condition's lack of symptoms and the discomfort often associated with topical treatments. In 2025, updated epidemiological data from the American Academy of Ophthalmology revealed that around 4.2 million adults in the United States were affected by glaucoma, emphasizing the vital importance of early and consistent management of ocular hypertension to avert irreversible vision impairment.

Market Driver

The principal catalyst for market growth is the increasing global prevalence of ocular hypertension and open-angle glaucoma, primarily propelled by an aging population more susceptible to optic nerve damage. This growing patient load creates a persistent and urgent need for sophisticated intraocular pressure management techniques that go beyond conventional topical treatments. As the occurrence of these conditions rises, healthcare systems are increasingly pressured to prioritize early intervention for sustained vision preservation. A November 2024 study in the Journal of Global Health, titled 'Global incidence and risk factors for glaucoma,' estimated the global incidence rate of primary open-angle glaucoma at 23.46 per 10,000 person-years for individuals aged 40 to 79, indicating a swift expansion of the target demographic that directly drives demand for glaucoma therapies and surgical options.

Concurrently, technological innovations, particularly in sustained-release drug delivery systems and Minimally Invasive Glaucoma Surgery (MIGS), are transforming the treatment paradigm by effectively tackling the persistent challenge of eye drop non-adherence. This innovation is fostering considerable commercial adoption as healthcare providers embrace implantable devices that ensure continuous medication release or enhance aqueous humor outflow. Glaukos Corporation's 'Fourth Quarter and Full Year 2024 Financial Results' in February 2025 reported record glaucoma net sales of $303.3 million, highlighting the strong market acceptance of these new interventional therapies. The wider industry trend also confirms this pivot toward surgical and device-based care; Alcon's February 2025 report showed total surgical net sales of $5.5 billion for fiscal year 2024, emphasizing the substantial financial scale and investment dedicated to advanced ophthalmic interventions.

Market Challenge

Patient non-adherence to long-term medication regimens presents a significant barrier to the growth of the Global Ocular Hypertension Treatment Market. This reluctance to maintain consistent therapy, often due to the absence of noticeable symptoms and the discomfort from side effects like ocular irritation, results in treatment discontinuation and lower prescription refill rates. As a direct consequence, pharmaceutical companies experience a loss of ongoing revenue, preventing the market from realizing its complete financial potential. The disparity between prescribed treatments and actual patient behavior introduces a considerable inefficiency in disease management, directly hindering market growth forecasts.

The magnitude of this challenge is further highlighted by the immense global prevalence of the condition, which, despite representing a vast potential consumer base, remains partly unreachable due to compliance problems. In 2025, the World Glaucoma Association reported an estimated 78 million people diagnosed with glaucoma globally. While this figure points to a substantial addressable market, the high rate of non-compliance means that a significant portion of this population remains effectively untreated or inadequately managed. This ongoing adherence gap restricts the successful widespread adoption of therapeutic agents and diminishes the overall impetus of the global treatment market.

Market Trends

The increasing availability of home-based intraocular pressure monitoring devices is transforming the management of ocular hypertension by enabling the detection of diurnal fluctuations often missed during sporadic clinical appointments. These portable technologies empower patients to continuously measure their pressure outside the clinical environment, supplying clinicians with extensive data to customize treatment plans and identify pressure spikes occurring outside regular office hours. This move towards remote, patient-focused monitoring is attracting commercial interest as healthcare providers aim to lessen the risks linked to uncontrolled pressure variability. Revenio Group's 'Financial Statements Release January 1 - December 31, 2024' in February 2025 reported full-year net sales of EUR 103.5 million, marking a 7.2 percent increase significantly attributed to robust sales growth in its home-use tonometer solutions.

Simultaneously, the incorporation of artificial intelligence into disease progression analysis is improving diagnostic accuracy. Deep learning techniques are now employed to identify subtle changes in the optic nerve at an earlier stage than conventional methods. These automated systems analyze extensive imaging datasets to provide objective risk evaluations, thereby minimizing the subjective variations inherent in manual human grading. This technological advancement allows for prompt intervention before irreversible vision loss sets in, addressing the crucial demand for scalable and precise screening tools in busy clinical settings. A news release from the American Academy of Ophthalmology in October 2025, 'Artificial Intelligence-Guided Glaucoma Screening Shows Promise,' highlighted a study where a new machine learning algorithm accurately identified glaucoma patients 88 to 90 percent of the time, surpassing the 79 to 81 percent accuracy achieved by trained human graders.

Key Market Players

  • Angelini Spa
  • Laboratorios Sophia
  • Neurim Pharmaceuticals Ltd
  • Nicox SA
  • Novartis AG.
  • Aerie Pharmaceuticals, Inc.
  • Abbvie, Inc
  • Angelini Pharma S.p.a.
  • Chong Kun Dang pharmaceutical Corp
  • Lee Pharma Ltd

Report Scope

In this report, the Global Ocular Hypertension Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Ocular Hypertension Treatment Market, By Type

  • Intraocular Hypertension
  • Glaucoma

Ocular Hypertension Treatment Market, By Route Of Administration

  • Oral
  • Parenteral
  • Other

Ocular Hypertension Treatment Market, By Distribution Channel

  • Retail Pharmacy
  • Online Pharmacy
  • Other

Ocular Hypertension Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Ocular Hypertension Treatment Market.

Available Customizations:

Global Ocular Hypertension Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Ocular Hypertension Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Intraocular Hypertension, Glaucoma)
    • 5.2.2. By Route Of Administration (Oral, Parenteral, Other)
    • 5.2.3. By Distribution Channel (Retail Pharmacy, Online Pharmacy, Other)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Ocular Hypertension Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Route Of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Ocular Hypertension Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Route Of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Ocular Hypertension Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Route Of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Ocular Hypertension Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Route Of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Ocular Hypertension Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Route Of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Ocular Hypertension Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Route Of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Ocular Hypertension Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Route Of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Ocular Hypertension Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Route Of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Ocular Hypertension Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Route Of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Ocular Hypertension Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Route Of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Ocular Hypertension Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Route Of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Ocular Hypertension Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Route Of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Ocular Hypertension Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Route Of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Ocular Hypertension Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Route Of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Ocular Hypertension Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Route Of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Ocular Hypertension Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Route Of Administration
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Ocular Hypertension Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Route Of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Ocular Hypertension Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Route Of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Ocular Hypertension Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Route Of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Ocular Hypertension Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Route Of Administration
        • 9.3.3.2.3. By Distribution Channel

10. South America Ocular Hypertension Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Route Of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Ocular Hypertension Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Route Of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Ocular Hypertension Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Route Of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Ocular Hypertension Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Route Of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Ocular Hypertension Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Angelini Spa
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Laboratorios Sophia
  • 15.3. Neurim Pharmaceuticals Ltd
  • 15.4. Nicox SA
  • 15.5. Novartis AG.
  • 15.6. Aerie Pharmaceuticals, Inc.
  • 15.7. Abbvie, Inc
  • 15.8. Angelini Pharma S.p.a.
  • 15.9. Chong Kun Dang pharmaceutical Corp
  • 15.10. Lee Pharma Ltd

16. Strategic Recommendations

17. About Us & Disclaimer